Symposium at the Sixth International Congress on Alzheimer's Disease and Related Disorders, Amsterdam, July 1998: Clinical trial designs for demonstrating disease-course-altering effects in dementia

Alzheimer Disease and Associated Disorders

Volumn 12, Issue 4, 1998, Pages 281-294

  Whitehouse, Peter J ^a,g   Kittner, Barbara ^b   Roessner, Martin ^b   Rossor, Martin ^c   Sano, Mary ^d   Thal, Leon ^e   Winblad, Bengt ^f  

^a University Alzheimer Center   (United States)

^b SANOFI   (France)

^c Dementia Research Group   (United Kingdom)

^d Columbia Univ Coll Phys Surgs ^*  (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^g Alzheimer Center   (United States)

Author keywords

Alzheimer disease (AD); Delay of disease progression; Dementia; Propentofylline; Selegiline; Staggered start design (SSD); Survival analysis; Trial design; Vascular dementia (VaD); Vitamin E ( tocopherol); Withdrawal design (WDD)

Indexed keywords

ALPHA TOCOPHEROL; ANTIINFLAMMATORY AGENT; ESTROGEN; PROPENTOFYLLINE; SCAVENGER; SELEGILINE; NOOTROPIC AGENT;

AGED; ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITION; CONFERENCE PAPER; DAILY LIFE ACTIVITY; DEMENTIA; DISEASE COURSE; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; MAJOR CLINICAL STUDY; METHODOLOGY; MULTIINFARCT DEMENTIA; PHASE 3 CLINICAL TRIAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; SURVIVAL; SYMPOSIUM; CONTROLLED CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; STATISTICS;

AGED; ALZHEIMER DISEASE; DEMENTIA; HUMANS; NOOTROPIC AGENTS; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; SURVIVAL ANALYSIS;

EID: 0032237793     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002093-199812000-00007     Document Type: Conference Paper

References (27)

1. Bodick N, Forette F, Hadler D, et al. Protocols to demonstrate slowing of Alzheimer disease progression. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord 1997;11(suppl 3):50-3.
2. Braak H, Braak E. Development of cytoskeletal changes and staging of Alzheimer related intraneuronal pathology. Neurobiol Aging 1994; 15:S141.
3. European Agency for the Evaluation of Medicinal Products. CPMP/EWP/553/95. Note for guidance on medicinal products in the treatment of Alzheimer's disease. Available at http://www.eudra.org/ emea.html. Accessed September 9, 1998.
4. Galasko D, Edland SD, Morris JC, Clark C, Mohs R, Koss E. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part XI. Clinical milestones in patients with Alzheimer's disease followed over 3 years. Neurology 1995;45:1451-5.
5. Grundman M, Petersen RC, Morris JC, Ferris S, Sano M, Farlow MR, et al. Rate of dementia of the Alzheimer type (DAT) in subjects with mild cognitive impairment. Neurology 1996;46:A403.
6. Karlsson I, Kittner B, Rother M, et al. A double-blind placebo-controlled study of the effects of withdrawing propentofylline therapy. Alzheimer Dis Assoc Disord 1998, in press.
7. Khachaturian Z. The five-five, ten-ten plan for Alzheimer's disease [editorial]. Neurobiol Aging 1992;13:197-8.
8. Kittner B, Roessner M, Rother M. Clinical trials in dementia with propentofylline. Ann NY Acad Sci 1997;826:307-16.
9. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. JAMA 1994;271:985-91.
10. Kramer-Ginsberg E, Mohs RC, Aryan M, et al. Clinical predictors of course for Alzheimer's patients in a longitudinal study: a preliminary report. Psychopharm Bull 1988;24:458-562.
11. Leber P. Observations and suggestions on antidementia drug development. Alzheimer Dis Assoc Disord 1996a;10(suppl 1):31-5.
12. Leber PD. FDA letter from Paul D. Leber, M.D., Director, Division of Neuropharmacological Drug Products, Office of Drug Evaluation, Center for Drug Evaluation and Research, February 20, 1996b.
13. Marcusson J, Rother M, Kittner B, et al. A 12-month, randomized placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R. Dement Geriatr Cogn Disord 1997;8:320-8.
14. Matthews KA, Shumaker SA, Bowen DJ, Langer RD, Hunt JR, Kaplan RM, et al. Women's health initiative: why now? what is it? what's new? Am Psychol 1997;52:101-16.
15. McGeer P, McGeer E. The inflammatory response of brain: implications for therapy of Alzheimer's and other neurodegenerative diseases. Brain Res Rev 1995;21:195-218.
16. Pischel T. Long-term efficacy and safety of propentofylline in patients with vascular dementia: results of a 12-month, placebo-controlled trial. Poster presented at the Sixth International Congress on Alzheimer's Disease and Related Disorders, July 1998, Amsterdam, The Netherlands.
17. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, and the Donepezil Study Group. A 24-week, double-blind placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998;50:136-45.
18. Rother M. Long-term efficacy and safety of propentofylline in patients with Alzheimer's disease: results of an 18-month, placebo-controlled trial. Poster presented at the Sixth International Congress on Alzheimer's Disease and Related Disorders, July 1998, Amsterdam, The Netherlands.
19. Sano M, Ernesto C, Klauber MR, Schafer K, Woodbury P, Thomas R, et al. Rationale and design of a multicenter study of selegiline and α-tocopherol in the treatment of Alzheimer's disease using novel clinical outcomes. Alzheimer Dis Assoc Disord 1996;10:132-40.
20. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997;24;336:1216-22.
21. Schubert P, Ogata T, Miyazaki H, et al. Pathological immune-reactions of glial cells in Alzheimer's Disease and possible sites of interference. J Neurotransmiss 1997a, in press.
22. Schubert P, Ogata T, Rudolphi K, et al. Support of homeostatic glial cell signaling: a novel therapeutic approach by propentofylline. Ann NY Acad Sci 1997b;826:337-47.
23. Stern Y, Folstein M, Albert M, Richards M, Miller L, Bylsma F, et al. Multi-center study of predictors of disease course in Alzheimer's disease (the "Predictors Study"): I. Study design, cohort description and intersite comparisons. Alzheimer Dis Assoc Disord 1993;7:3-21.
24. Study 304. Efficacy and safety study of propentofylline (HWA 285) versus placebo in patients with Alzheimer's disease. HWA285/6/MN/304/DZ. March 6, 1998. Data on file, Hoechst Marion Roussel.
25. Study 305. Efficacy and safety study of propentofylline (HWA 285) versus placebo in patients with vascular dementia. HWA285/6/MN/305/DZ. March 6, 1998. Data on file, Hoechst Marion Roussel.
26. Tariot PN, Mack JL, Patterson MB, et al. The Behavior Rating Scale for Dementia of the Consortium to Establish a Registry for Alzheimer's Disease. The Behavioral Pathology Committee of the Consortium to Establish a Registry for Alzheimer's Disease. Am J Psychiatry 1995;152:1349-57.
27. Thoenen H, Barde YA. Physiology of nerve growth factor. Physiol Rev 1980;60:1284-335.